Collaboration between Cannabis and the University of Valencia (Universitat Politecnica de Valencia or UPV) led to the development of a THC-free cannabis that contains approximately 15% CBG - approximately 100 compared to normal cannabis.
Canavigrul (CBG), known as cannabinoid parent, is the first cannabinoid found in the cannabis plant in its growth process and is actually the source of all other cannabinoids. When the plant reaches the flowering stage, it releases enzymes that convert the CBG to other cannabinoids such as THC and CBD.
"When the plant grows, CBG is converted into a biosynthetic process for THC, CBD, and other cannabinoids. As a result, the CBG itself has disappeared and remains slightly in the plant, Explains Salvador Soler, a researcher at the Technical University of Valencia, one of 5 institutions in Spain who have a license to grow cannabis for research purposes.
According to Hemp Trading CEO Ernesto Llosá, the company has managed to block some of the biosynthetic process involved in the new strain it developed with the university, thus preventing the CBG in the plant from becoming other cannabinoids.
As a result, the CBG concentration in the new strain is significantly higher than the existing cannabis varieties, which contain only its residues. Another advantage of the new strain is that it does not produce THC, not even in minuscule concentrations, making it completely legal in most European countries.
"We were able to produce a totally THC-free cannabis plant, with CBG concentration higher than 15%, where the average concentration is usually 0.1-0.5%," says Leyosa. The highest concentration of CBG previously recorded in cannabis was about 3% in the strain called Mickey Kush.
"Thanks to the development CBG can be obtained in huge quantities, which will open the door to its large-scale production legally, as well as studies that will examine its medicinal properties," he adds.
CBG is a cannabinoid that has not yet been studied in depth, and partly because of its minimal concentration in the plant. Yet, Studies Initial suggested that CBG may be effective in relieving pain and reducing inflammation caused by inflammatory bowel diseases such as Crohn's, As well as Slowing down the colon cancer development process.
In the article Of the neurologist and cannabinoid researcher Dr. Ethan Russo, published in the British Journal of Pharmacology, notes that CBG has antifungal properties, and it also inhibits the overproduction of the keratinocyte skin cells that occurs in the disease Psoriasis.
Studies Suggested that CBG may be an effective treatment for glaucoma, as it lowers intraocular pressure. In an experiment on cats CBG was found to be more effective than CBD in lowering intraocular pressure, so it is probably more effective in treating the disease.
Research Of 2016 found that CBG was also particularly effective in encouraging appetite with a similar effect to the manchise effect of THC intake, only with no methylated effect.